Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

C4 Therapeutics (CCCC) Leases (2019 - 2026)

C4 Therapeutics has reported Leases over the past 8 years, most recently at $39.1 million for Q1 2026.

  • For Q1 2026, Leases fell 30.05% year-over-year to $39.1 million; the TTM value through Mar 2026 reached $39.1 million, down 30.05%, while the annual FY2025 figure was $40.5 million, 29.55% down from the prior year.
  • Leases for Q1 2026 was $39.1 million at C4 Therapeutics, down from $40.5 million in the prior quarter.
  • Over five years, Leases peaked at $74.8 million in Q1 2022 and troughed at $39.1 million in Q1 2026.
  • A 5-year average of $60.4 million and a median of $62.4 million in 2024 define the central range for Leases.
  • Biggest five-year swings in Leases: skyrocketed 484.68% in 2022 and later crashed 30.05% in 2026.
  • Year by year, Leases stood at $70.1 million in 2022, then decreased by 8.79% to $64.0 million in 2023, then fell by 10.04% to $57.5 million in 2024, then dropped by 29.55% to $40.5 million in 2025, then decreased by 3.56% to $39.1 million in 2026.
  • Business Quant data shows Leases for CCCC at $39.1 million in Q1 2026, $40.5 million in Q4 2025, and $42.0 million in Q3 2025.